AR030432A1 - Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. - Google Patents
Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.Info
- Publication number
- AR030432A1 AR030432A1 ARP010103092A ARP010103092A AR030432A1 AR 030432 A1 AR030432 A1 AR 030432A1 AR P010103092 A ARP010103092 A AR P010103092A AR P010103092 A ARP010103092 A AR P010103092A AR 030432 A1 AR030432 A1 AR 030432A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- defined above
- represents hydrogen
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 108090000461 Aurora Kinase A Proteins 0.000 abstract 1
- 102100032311 Aurora kinase A Human genes 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El uso de derivados de quinazolina de formula (1) o una sal, éster o amida del mismo; en la cual X es O, o S, S(O) o S(O)2, o NR6 donde R6 es hidrogeno o alquilo C1-6; R5 es un anillo heteroaromático de 5 miembros opcionalmente sustituido, R1, R2, R3, R4 están independientemente seleccionados entre halo, ciano, nitro, trifluormetilo, alquilo C1-3, NR7R8 (donde R7 y R8 que pueden ser iguales o diferentes, representan cada uno hidrogeno o alquilo C1-3), o -X1R9 (donde X1 representa un enlace directo, -O-, -CH2-, -OCO-, carbonilo, -S-, -SO-, -SO2-, -NR10CO-, -CONR11-, -SO2NR12-, -NR13SO2-, o NR14 - (donde R10, R11, R12, R13 y R14 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3), y R9 está seleccionado entre uno de los siguientes grupos: 1) hidrogeno o alquilo C1-5 que puede estar no sustituido o puede estar sustituido con uno o más grupos seleccionados de hidroxi, fluor o amino, 2) alquilo C1-5X2COR15 (donde X2 representa -O- o -NR16- (en el cual R15 representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3 y R16 representa alquilo C1-3, -NR17R18 o -OR19 (donde R17, R18 y R19, que pueden ser iguales o diferentes, representan cada uno hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3)); 3) alquilo C1-5X3R20 (donde X3 representa -O-, -S-, -SO-, -SO2-, -OCO-, -NR21CO-, -CONR22-, -SO2NR23-, -NR24SO2- o -NR25- (donde R21, R22, R23, R24 y R25 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R20 representa hidrogeno, alquilo C1-3, ciclopentilo, ciclohexilo o un grupo heterocíclico saturado de 5-6 miembros con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo alquilo C1-3 puede ser portador de 1 o 2 sustituyentes seleccionados de oxo, hidroxi, halogeno y alcoxi C1-4 y donde el grupo cíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, y alcoxi C1-4; 4) alquilo C1-5 X4 alquilo C1-5 X5R26 (donde X4 y X5, que pueden ser iguales o diferentes, son cada uno -O-, -S-, -SO-, -SO2-, -NR27CO-, -CONR28-, -SO2NR29-, -NR30SO2- o -NR31- (donde R27, R28, R29, R30 y R31 cada uno independientemente representa hidrogeno, alquilo C1-3 y alcoxi C1-3 alquilo C2-3) y R26 representa hidrogeno o alquilo C1-3); 5) R32 (donde R32 es un grupo heterocíclilo saturado de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo heterocíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4, alcoxi C1-4 alquilo C1-4 y alquilsulfonil C1-4 alquilo C1-4); 6) alquilo C1-5 R32 (donde R32 es tal como se ha definido anteriormente); 7) alquenilo C2-5 R32 (donde R32 es tal como se ha definido anteriormente); 8) alquinilo C2-5R32 (donde R32 es tal como se ha definido anteriormente); 9) R33 (donde R33 representa un grupo piridona, fenilo o un grupo heterocíclico aromático de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-3 heterátomos seleccionados de O, N y S, donde el grupo piridona, fenilo o heterocíclico aromático puede ser portador de hasta 5 sustituyentes sobre un átomo de carbono asequible, seleccionados de hidroxi, halogeno, amino, alquilo C1-4, alcoxi C1-4, hidroxialquilo C1-4, aminoalquilo C1-4, alquilamino C1-4, hidroxialcoxi C1-4, carboxi, trifluormetilo, ciano, -CONR34R35 y -NR36COR37 (donde R34, R35,R36 y R37, que pueden ser iguales o diferentes, representa cada uno hidrogeno, alquilo C1-4 o alcoxi C1-3 alquilo C2-3)); 10) alquilo C1-5R33 (donde R33 es tal como se ha definido anteriormente); 11) alquenilo C2-5 R33(donde R33 es tal como se ha definido anteriormente); 12) alquinilo C2-5R33 (donde R33 es tal como se ha definido anteriormente); 13) alquilo C1-5X6R33 (donde X6 representa -O-, -S-, -SO2-, -NR38CO-, -CONR39-, -SO2NR40-, -NR41SO2- o -NR42- (donde R38, R39, R40, R41 y R42 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 14) alquenilo C2-5X7R33 (donde X7 representa -O-, -S-, -SO-, -SO2-, -NR43CO-, -CONR44-, -SO2NR45, -NR46SO2-, o -NR47- (donde R43, R44, R45, R46 y R47 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 15) alquinilo C2-5X8R33 (donde X8 representa -O-, -S-, -SO-, -SO2-, -NR48CO-, -CONR49-, -SO2NR50-, -NR51SO2- o -NR52- (donde R48, R49, R50, R51 y R52 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 16) alquilo C1-3X9 alquilo C1-3R33 (donde X9 representa -O-, -S-, -SO-, -SO2-, -NR53CO-, -CONR54-, -SO2NR55-, -NR56SO2- o -NR57- (donde R53, R54, R55, R56 y R57 cada uno de los cuales representa independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente) y 17) alquilo C1-3X9 alquilo C1-3R32 (donde X9 y R28 son tal como se han definido anteriormente); que se usa en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00401842 | 2000-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030432A1 true AR030432A1 (es) | 2003-08-20 |
Family
ID=8173742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103092A AR030432A1 (es) | 2000-06-28 | 2001-06-28 | Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6919338B2 (es) |
| EP (1) | EP1299381B1 (es) |
| JP (1) | JP2004501914A (es) |
| KR (1) | KR20030014411A (es) |
| CN (1) | CN1267431C (es) |
| AR (1) | AR030432A1 (es) |
| AT (1) | ATE394102T1 (es) |
| AU (1) | AU2001266505A1 (es) |
| BG (1) | BG107376A (es) |
| BR (1) | BR0111754A (es) |
| CA (1) | CA2412592A1 (es) |
| CZ (1) | CZ20024120A3 (es) |
| DE (1) | DE60133897D1 (es) |
| EE (1) | EE200200715A (es) |
| ES (1) | ES2305081T3 (es) |
| HK (1) | HK1053124A1 (es) |
| HU (1) | HUP0301236A2 (es) |
| IL (1) | IL153246A0 (es) |
| IS (1) | IS6656A (es) |
| MX (1) | MXPA02011974A (es) |
| NO (1) | NO20026010L (es) |
| NZ (1) | NZ522696A (es) |
| PL (1) | PL360439A1 (es) |
| RU (1) | RU2283311C2 (es) |
| SK (1) | SK18102002A3 (es) |
| WO (1) | WO2002000649A1 (es) |
| ZA (1) | ZA200209412B (es) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0302172A2 (hu) | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| KR100909665B1 (ko) * | 2000-12-21 | 2009-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
| RU2323215C2 (ru) | 2001-12-24 | 2008-04-27 | Астразенека Аб | Замещенные производные хиназолина как ингибиторы ауроракиназы |
| RU2004126671A (ru) * | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
| WO2003075921A2 (en) * | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| AU2003218215A1 (en) * | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| ATE489384T1 (de) * | 2002-05-06 | 2010-12-15 | Vertex Pharma | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| EP1532145B1 (en) | 2002-08-02 | 2006-09-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
| GB0221245D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
| WO2004058781A1 (en) | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| CN101074227B (zh) * | 2002-12-24 | 2010-09-29 | 阿斯利康(瑞典)有限公司 | 膦酰氧基喹唑啉衍生物及其药物用途 |
| EP1575946A1 (en) * | 2002-12-24 | 2005-09-21 | AstraZeneca AB | Quinazoline compounds |
| US7601718B2 (en) * | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| EP1613619B1 (en) * | 2003-04-16 | 2008-03-26 | AstraZeneca AB | Quinazoline derivatives for treatment of cancer |
| EP1635823A1 (en) * | 2003-05-20 | 2006-03-22 | TransTech Pharma Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| WO2004105764A1 (en) * | 2003-06-02 | 2004-12-09 | Astrazeneca Ab | (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| SI2213661T1 (sl) | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
| US20080051414A1 (en) * | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| US20090143399A1 (en) * | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| US20090099165A1 (en) * | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| DE602004022318D1 (de) * | 2003-10-14 | 2009-09-10 | Supergen Inc | Proteinkinaseinhibitoren |
| EP1678149A2 (en) * | 2003-10-31 | 2006-07-12 | Neurogen Corporation | 4-amino(aza)quinoline derivatives as capsaicin receptor agonists |
| CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
| WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| US8119684B2 (en) * | 2003-12-30 | 2012-02-21 | Dana-Farber Cancer Institute, Inc. | Thiophene derivatives for up-regulating HLA-DM activity |
| US7687502B2 (en) * | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
| WO2006023931A2 (en) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
| US20090036485A1 (en) * | 2004-10-12 | 2009-02-05 | Frederic Henri Jung | Quinoline derivatives |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| CN1854130B (zh) * | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0510963D0 (en) * | 2005-05-28 | 2005-07-06 | Astrazeneca Ab | Chemical compounds |
| JP2009504771A (ja) * | 2005-08-18 | 2009-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラジンキナーゼ阻害剤 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2006311830B2 (en) * | 2005-11-03 | 2013-03-14 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| EP1785420A1 (en) * | 2005-11-14 | 2007-05-16 | 4Sc Ag | Thiazole analogues and uses thereof |
| AU2007208351C1 (en) | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| WO2007099323A2 (en) * | 2006-03-02 | 2007-09-07 | Astrazeneca Ab | Quinoline derivatives |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2007113005A2 (en) * | 2006-04-03 | 2007-10-11 | European Molecular Biology Laboratory (Embl) | 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors |
| MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8236823B2 (en) * | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| US20080207632A1 (en) * | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
| CA2668429A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| WO2008077086A1 (en) * | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| CA2680029A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| CA2679701A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
| CA2679884A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| MX2009010517A (es) | 2007-04-05 | 2009-10-19 | Amgen Inc | Moduladores de cinasa aurora y metodos de uso. |
| WO2008128009A2 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5572087B2 (ja) * | 2007-05-02 | 2014-08-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害として有用なアミノピリミジン |
| JP5389786B2 (ja) * | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害として有用なアミノピリミジン |
| WO2008137619A2 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| AU2008257044A1 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| ES2395581T3 (es) * | 2007-06-20 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibidores de quinasas janus |
| EP2170842A1 (en) * | 2007-06-21 | 2010-04-07 | Irm, Llc | Protein kinase inhibitors and methods for using thereof |
| EP2176261B1 (en) * | 2007-07-31 | 2012-12-19 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
| DE102008015032A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte Pyrazolamide und ihre Verwendung |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| US8404694B2 (en) * | 2008-03-20 | 2013-03-26 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
| EP2323622A1 (en) * | 2008-09-03 | 2011-05-25 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| ES2489040T3 (es) | 2008-12-03 | 2014-09-01 | The Scripps Research Institute | Cultivos de células madre |
| DE102008062878A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte Furancarboxamide und ihre Verwendung |
| DE102008062863A1 (de) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung |
| AU2010204619B2 (en) | 2009-01-16 | 2016-08-11 | Exelixis, Inc. | Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| BRPI1008325A2 (pt) * | 2009-02-11 | 2020-08-25 | Merck Patent Gmbh | carboxamidas azaeterocíclicas de amino |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| ES2467923T3 (es) | 2009-09-30 | 2014-06-13 | Transtech Pharma, Llc | Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer |
| JP2013523894A (ja) | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| WO2012066578A2 (en) * | 2010-11-18 | 2012-05-24 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| US8785459B2 (en) * | 2011-12-27 | 2014-07-22 | Development Center For Biotechnology | Quinazoline compounds as kinase inhibitors |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| PL2634185T3 (pl) | 2012-03-02 | 2016-06-30 | Sareum Ltd | Inhibitory kinazy TYK2 |
| CN103788085B (zh) * | 2012-10-31 | 2016-09-07 | 复旦大学 | 2-（喹唑啉-4-氨基）-5-噻唑甲酰胺类衍生物及其生物药物用途 |
| CN104098551B (zh) * | 2013-04-03 | 2019-03-22 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物 |
| CN105555315B (zh) | 2013-09-16 | 2019-05-07 | 阿斯利康(瑞典)有限公司 | 治疗性聚合物纳米颗粒及其制备和使用方法 |
| CN108473435A (zh) | 2015-10-05 | 2018-08-31 | 纽约市哥伦比亚大学理事会 | 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗 |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| EP4025565A1 (en) * | 2019-09-06 | 2022-07-13 | Inflazome Limited | Nlrp3 inhibitors |
| CN110746398A (zh) * | 2019-10-18 | 2020-02-04 | 刘沛友 | 4-杂环取代喹唑啉类衍生物及其制备方法和用途 |
| CN111574473A (zh) * | 2020-06-04 | 2020-08-25 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 一种氨基噻唑类化合物的合成方法 |
| CN113311166B (zh) * | 2021-04-28 | 2022-10-28 | 新疆农垦科学院 | 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法 |
| CN115557601B (zh) * | 2022-11-08 | 2024-11-08 | 成都理工大学 | 生物质微球及其制备方法与应用、生物反应器、地下井 |
| WO2024184550A1 (en) * | 2023-03-09 | 2024-09-12 | Cancer Research Technology Limited | Biarylamide derivatives and their use as pkmyt1 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870725A (en) * | 1971-03-30 | 1975-03-11 | Lilly Industries Ltd | Nitrothiazole derivatives |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| IL117620A0 (en) * | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| ES2241324T3 (es) * | 1998-10-08 | 2005-10-16 | Astrazeneca Ab | Derivados de quinazolina. |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
-
2001
- 2001-06-21 US US10/311,916 patent/US6919338B2/en not_active Expired - Fee Related
- 2001-06-21 CZ CZ20024120A patent/CZ20024120A3/cs unknown
- 2001-06-21 EP EP01944061A patent/EP1299381B1/en not_active Expired - Lifetime
- 2001-06-21 KR KR1020027017913A patent/KR20030014411A/ko not_active Application Discontinuation
- 2001-06-21 AT AT01944061T patent/ATE394102T1/de not_active IP Right Cessation
- 2001-06-21 WO PCT/SE2001/001450 patent/WO2002000649A1/en active IP Right Grant
- 2001-06-21 BR BR0111754-8A patent/BR0111754A/pt not_active IP Right Cessation
- 2001-06-21 DE DE60133897T patent/DE60133897D1/de not_active Expired - Fee Related
- 2001-06-21 AU AU2001266505A patent/AU2001266505A1/en not_active Abandoned
- 2001-06-21 CN CNB018146201A patent/CN1267431C/zh not_active Expired - Fee Related
- 2001-06-21 CA CA002412592A patent/CA2412592A1/en not_active Abandoned
- 2001-06-21 MX MXPA02011974A patent/MXPA02011974A/es unknown
- 2001-06-21 JP JP2002505773A patent/JP2004501914A/ja active Pending
- 2001-06-21 PL PL01360439A patent/PL360439A1/xx not_active Application Discontinuation
- 2001-06-21 SK SK1810-2002A patent/SK18102002A3/sk unknown
- 2001-06-21 HU HU0301236A patent/HUP0301236A2/hu unknown
- 2001-06-21 RU RU2003102389/04A patent/RU2283311C2/ru not_active IP Right Cessation
- 2001-06-21 ES ES01944061T patent/ES2305081T3/es not_active Expired - Lifetime
- 2001-06-21 IL IL15324601A patent/IL153246A0/xx unknown
- 2001-06-21 EE EEP200200715A patent/EE200200715A/xx unknown
- 2001-06-21 NZ NZ522696A patent/NZ522696A/en unknown
- 2001-06-28 AR ARP010103092A patent/AR030432A1/es not_active Application Discontinuation
-
2002
- 2002-11-19 ZA ZA200209412A patent/ZA200209412B/en unknown
- 2002-12-11 BG BG107376A patent/BG107376A/bg unknown
- 2002-12-13 NO NO20026010A patent/NO20026010L/no unknown
- 2002-12-17 IS IS6656A patent/IS6656A/is unknown
-
2003
- 2003-07-31 HK HK03105517A patent/HK1053124A1/xx not_active IP Right Cessation
-
2005
- 2005-03-02 US US11/070,057 patent/US20060046987A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060046987A1 (en) | 2006-03-02 |
| ZA200209412B (en) | 2004-02-19 |
| CA2412592A1 (en) | 2002-01-03 |
| KR20030014411A (ko) | 2003-02-17 |
| CN1267431C (zh) | 2006-08-02 |
| HK1053124A1 (en) | 2003-10-10 |
| PL360439A1 (en) | 2004-09-06 |
| RU2283311C2 (ru) | 2006-09-10 |
| CZ20024120A3 (cs) | 2003-03-12 |
| BR0111754A (pt) | 2003-04-29 |
| NO20026010D0 (no) | 2002-12-13 |
| MXPA02011974A (es) | 2004-09-06 |
| EP1299381A1 (en) | 2003-04-09 |
| BG107376A (bg) | 2003-09-30 |
| ES2305081T3 (es) | 2008-11-01 |
| WO2002000649A9 (en) | 2007-09-20 |
| IS6656A (is) | 2002-12-17 |
| NO20026010L (no) | 2002-12-13 |
| ATE394102T1 (de) | 2008-05-15 |
| EP1299381B1 (en) | 2008-05-07 |
| SK18102002A3 (sk) | 2003-07-01 |
| DE60133897D1 (de) | 2008-06-19 |
| AU2001266505A1 (en) | 2002-01-08 |
| IL153246A0 (en) | 2003-07-06 |
| CN1496364A (zh) | 2004-05-12 |
| WO2002000649A1 (en) | 2002-01-03 |
| JP2004501914A (ja) | 2004-01-22 |
| EE200200715A (et) | 2004-08-16 |
| HUP0301236A2 (hu) | 2003-10-28 |
| NZ522696A (en) | 2004-08-27 |
| US6919338B2 (en) | 2005-07-19 |
| US20030187002A1 (en) | 2003-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030432A1 (es) | Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. | |
| AR038476A1 (es) | Derivados de quinazolina | |
| AR037881A1 (es) | Uso de derivados de oxindol | |
| AR045691A1 (es) | Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos | |
| ES2128791T3 (es) | Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos. | |
| HUP0400365A2 (hu) | 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR038052A1 (es) | Derivados de quinazolina como inhibidores de auroraquinasas | |
| ATE330959T1 (de) | Allosterische adenosin-rezeptor-modulatore | |
| AR025735A1 (es) | Compuestos terapeuticos | |
| HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| CR8859A (es) | Derivados de piridina | |
| HUP0300894A2 (hu) | Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626572A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| HUP0105414A2 (hu) | Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| SE0102438D0 (sv) | New compounds | |
| NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
| CY1112178T1 (el) | Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR061918A1 (es) | Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| EE200100491A (et) | Tetrahüdropüraani derivaadid, nende saamine ja kasutamine ravimainetena ning neid sisaldav farmatseutiline kompositsioon | |
| PE20020759A1 (es) | Derivados de bencilamina con base prolina como inhibidores de trombina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |